Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

MDS 2020 | Lenalidomide, mutations & MDS outcomes

Valeria Santini, MD, University of Florence, Florence, Italy, discusses the use of lenalidomide in the treatment of myelodysplastic syndromes (MDS) and the impact of different genetic aberrations on the efficacy of this drug. Dr Santini goes on to outline the use of immunosuppressive treatment in MDS. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).